FGEN FibroGen
WatchlistFibroGen News
FibroGen/Astellas' EVRENZO (Roxadustat) Making In-Roads in European Market as In-Class Challenger, Akebia/Medice's VAFSEO (Vadadustat), Prepares for Launch in Early 2024.
Exton, Pennsylvania, Dec. 08, 2023 (GLOBE NEWSWIRE) -- EVRENZO made history as the initial hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to receive EU approval in August 2021, securing its position by
Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), BioNTech SE (BNTX) and Sensei Biotherapeutics (SNSE)
FibroGen: Q3 Earnings Snapshot
FibroGen GAAP EPS of -$0.65 Beats by $0.02, Revenue of $40.1M Beats by $3.26M
Earnings Scheduled For November 6, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million. • Gerdau (NYSE:GGB) is estimated to report qua
FibroGen Q3 2023 Earnings Preview
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation
FibroGen Names Thane Wettig as Permanent CEO
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 311 stocks hit new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Bristol-Myers Squibb Company Common Stock (NYSE:BMY) is the largest company in terms of market cap to set
FibroGen(FGEN.US) Director Sells US$2,060 in Common Stocks
$FibroGen(FGEN.US)$ Director Henderson Jeffrey William sold 2,000 shares of Common Stocks on Sep 1, 2023 at an average price of $1.03 for a total value of $2,060.Source: Announcement What is statement
U.S. Shares Higher at Close of Trade; Dow Jones Industrial Average up 0.11%
Express News | FibroGen Shares Are Trading Lower After the Company's Phase 3 Trial of Pamrevlumab Did Not Meet Its Primary Endpoint.
NanoVibronix, Outlook Therapeutics, FibroGen Among Healthcare Movers
Sector Update: Health Care Stocks Mixed Premarket Wednesday
Health care stocks were mixed premarket Wednesda, with the Health Care Select Sector SPDR Fund (XLV) slightly higher recently while the iShares Biotechnology ETF (IBB) were inactive. Outlook Therapeut
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersNanoVibronix (NASDAQ:NAOV) stock increased by 71.0% to $2.48 during Wednesday's pre-market session. The company's market cap stands at $4.1 million. Aravive (NASDAQ:ARAV) stock moved upwards by
Three In A Row: FibroGen's Investigational Drug Flunks In Another Study For Rare Disease In Young Boys
Tuesday, FibroGen Inc (NASDAQ:FGEN) announced topline data from the Phase 3 LELANTOS-2 trial of pamrevlumab for ambulatory patients with Duchenne muscular dystrophy (DMD) on background systemic cortic
FibroGen (NASDAQ: FGEN) Tumbles After Setback in Phase 3 DMD Trial
Biggest Stock Movers Today: Ambarella, HPQ, Box and More
FibroGen's Pamrevlumab Doesn't Meet Goals In Phase III LELANTOS-2 Trial; Stock Down In Pre-market
FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%